THE COMPLETE GUIDE TO GENICULATE ARTERY EMBOLIZATION (GAE)

GAE is a minimally invasive outpatient procedure that reduces knee osteoarthritis pain by blocking the abnormal inflammatory blood vessels that develop around arthritic joints. A thin catheter is guided through a small puncture in the upper thigh to the tiny arteries around the knee using real-time X-ray imaging. Microscopic beads are injected to block the inflammatory vessels, breaking the pain cycle. The procedure takes one to two hours under moderate sedation, and most patients go home the same day and return to normal activities within one to two days.

Approximately 70 percent of patients experience at least 50 percent pain reduction. At twelve months, 78 percent met clinically meaningful improvement thresholds. Pain scores typically drop from 8 out of 10 to 3 out of 10 within the first week. At twenty-four months, 72 percent of initial responders maintained their improvement. Only 5.2 percent of patients progressed to knee replacement within two years. Best results occur in patients with mild to moderate osteoarthritis (Kellgren-Lawrence grades 1-3).

GAE is a same-day outpatient procedure with one-to-two-day recovery, moderate sedation, no incisions, and no bone or tissue alteration. Knee replacement requires general anesthesia, hospital admission, and three to six months of recovery. GAE costs $8,000–$15,000 versus $30,000–$50,000 or more. However, knee replacement provides longer-lasting results (15–20 years). GAE is best understood as a bridge that provides meaningful relief while preserving all future surgical options.

GAE has an excellent safety profile. Zero major complications were reported in the largest meta-analysis of 270 patients. The most common side effect is temporary skin discoloration near the knee (approximately 11 percent, resolves on its own). Groin access site bruising occurs in 10 to 17 percent (similar to any catheter procedure). Minor temporary numbness or tingling in 1 to 10 percent, resolving within 14 days. Only 0.3 percent required hospitalization. Compare this to knee replacement, which carries 1–2 percent infection risk, 1–3 percent blood clot risk, and requires general anesthesia.

Most patients experience relief for one to four years, depending on the severity of their arthritis. Milder arthritis (grades 1–2) tends to produce longer-lasting results. Among patients who respond well at twelve months, 72 percent maintain that improvement at twenty-four months. If pain eventually returns, GAE can be safely repeated — only 8.3 percent needed repeat treatment within two years. Importantly, all future treatment options including knee replacement remain fully available.

Total cost without insurance is $8,000 to $15,000. With commercial insurance (BCBS Alabama, UnitedHealthcare), typical out-of-pocket is $1,500 to $2,500. Medicare Part B covers approximately 80 percent; with Medigap, often zero after the $240 deductible. TRICARE covers GAE when medically necessary. Our team verifies your coverage and handles prior authorization.

The procedure itself is performed under moderate conscious sedation — similar to what you would receive for a colonoscopy. You are relaxed and comfortable. The puncture site in the upper thigh is numbed with local anesthetic, and most patients do not feel pain during the procedure. After GAE, mild knee soreness lasting about a week is common and easily managed with over-the-counter ibuprofen. Most patients describe recovery as surprisingly easy.

Yes, absolutely. GAE makes no structural changes to the knee joint whatsoever. Studies confirm successful knee replacement after prior GAE. GAE is specifically designed as a bridge — reducing pain while preserving every future treatment option. Only 5.2 percent of GAE patients needed knee replacement within two years, but those who did had no complications related to the prior embolization.

The best candidates are adults with chronic knee osteoarthritis pain lasting six months or longer who have tried conservative treatments (physical therapy, medications, cortisone injections) without lasting relief. Ideal for patients with Kellgren-Lawrence grades 1–3, those who want to delay or avoid knee replacement, those who cannot tolerate surgery due to medical conditions, and those too young for prosthetic knee longevity limitations. Patients with higher BMI and younger age actually showed better outcomes in clinical studies.

Yes. Medicare Part B typically covers GAE when medically necessary. Medicare pays approximately 80 percent of the approved amount. With Original Medicare alone, expect $1,500 to $2,500 out of pocket. With a Medigap supplement (Plan G or N), often zero after the $240 annual deductible. Medicare Advantage plans cover GAE for approximately $75 depending on the plan. Prior authorization with documentation of failed conservative treatment is generally required.

Cortisone provides temporary relief lasting weeks to months and is limited to three to four injections per year. Repeated cortisone may accelerate cartilage damage. GAE provides longer-lasting relief (one to four years) by blocking the abnormal inflammatory blood vessels rather than temporarily suppressing inflammation. A 2024 analysis found GAE was more cost-effective than cortisone over a four-year period. If your cortisone injections are providing shorter relief each time, GAE may offer a more durable alternative.

Despite similar names, these are fundamentally different procedures. GAE (geniculate artery embolization) blocks abnormal inflammatory blood vessels, targeting the cause of inflammation and pain. Genicular nerve ablation (radiofrequency ablation or RFA) burns the nerves around the knee to block pain signals, masking the symptom without addressing inflammation. Both are minimally invasive. RFA typically requires repeat treatment at approximately twelve months. A 2024 cost-effectiveness analysis found GAE had higher probability of cost-effectiveness than RFA over four years.

GAE is performed by interventional radiologists, a different medical specialty from orthopedic surgery. Many orthopedic surgeons are aware of GAE but may not yet routinely discuss it since the procedure is relatively new for knee osteoarthritis (first performed in 2015, with research expanding rapidly). The American Academy of Orthopaedic Surgeons published a 2025 review recognizing GAE as an emerging minimally invasive technique. Awareness is growing as clinical evidence builds. GAE is meant to complement orthopedic care, not replace it.

Yes. Clinical studies include patients who received bilateral GAE. Typically, knees are treated one at a time in separate sessions spaced several weeks apart. This allows the care team to monitor your response to the first procedure before treating the second knee. Some providers have treated both knees in a single session in select cases.

GAE targets the abnormal inflammatory blood vessels (neovascularity) that develop in arthritic joints and drive the pain and swelling cycle. By reducing this inflammatory environment, GAE addresses a key driver of osteoarthritis symptoms. However, GAE does not reverse structural cartilage damage or regrow cartilage. It is best understood as a treatment that breaks the inflammation-pain cycle, providing meaningful and lasting relief while preserving joint function and all future treatment options.